IONIS Pharmaceuticals (“ISIS Pharmaceuticals”until December 2015) proposed the use of ASOs (ISIS333611) as a therapeutic strategy for ALS patients carrying mutations in the SOD1 gene. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.